<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is known as a powerful regulator of white blood cell proliferation and differentiation in mammals </plain></SENT>
<SENT sid="1" pm="."><plain>We, and others, have shown that G-CSF is effective in treating <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rodents, both relating to <z:mpath ids='MPATH_124'>infarct</z:mpath> size as well as functional recovery </plain></SENT>
<SENT sid="2" pm="."><plain>G-CSF and its receptor are expressed by neurons, and G-CSF regulates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and neurogenesis, providing a rational basis for its beneficial short- and long-term actions in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, G-CSF may contribute to re-endothelialisation and arteriogenesis in the vasculature of the ischemic penumbra </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to these trophic effects, G-CSF is a potent neuroprotective factor reliably reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size in different <z:hpo ids='HP_0001297'>stroke</z:hpo> models </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Here, we have further delayed treatment and studied effects of G-CSF on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model and functional outcome in the cortical photothrombotic model </plain></SENT>
<SENT sid="6" pm="."><plain>In the MCAO model, we applied a single dose of 60 microg/kg bodyweight G-CSF in rats 4 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was determined 24 h after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In the rat photothrombotic model, we applied 10 microg/kg bodyweight G-CSF daily for a period of 10 days starting either 24 or 72 h after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>G-CSF both decreased <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the MCAO model, and improved recovery in the photothrombotic model at delayed timepoints </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: These data further strengthen G-CSF's profile as a unique candidate <z:hpo ids='HP_0001297'>stroke</z:hpo> drug, and provide an experimental basis for application of G-CSF in the post-<z:hpo ids='HP_0001297'>stroke</z:hpo> recovery phase </plain></SENT>
</text></document>